The disease specificity of the NAb increase was here magnified by the inclusion not only of healthy controls, but also of patients affected by a variety of neurodegenerative disorders, such as AD—wherein an altered TDP-43 proteostasis is not expected, although this consideration has been recently challenged, as reported inthe case of “LATE”17)—and FTLD that could, at least in some cases, share a TDP-43 pathology. Here, TARDBP is linked to Alzheimer disease.